Search
Ascendis Pharma A/S
ASNDAdd to Watchlist
232.060USD
-32.860-12.40%
Market hours 09/15, 12:56（ET）
15.36BMarket Cap
33.44P/E TTM
Ascendis Pharma A/S (ASND) Stock Price Target & Forecast
Analyst Rating
Based on 20 analysts giving stock ratings to Ascendis Pharma A/S in the past month.
Buy
10 Strong Buy
10 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
316.564USD+20.13%
ASND Analyst Recommendation Trends
In the current month, ASND has received 10 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. ASND average Analyst price target in the last month is 316.564.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
10
10
9
9
9
9
9
9
10
10
9
9
9
9
8
8
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
20
20
18
18
18
18
17
17
ASND Analyst Rating for Peer Comparison
Updated: Sep 14, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
argenx SE
ARGX
10
13
3
0
0
26
IQVIA Holdings Inc
IQV
7
12
6
0
0
25
Insmed Inc
INSM
7
17
0
0
0
24
CRISPR Therapeutics AG
CRSP
4
9
11
0
0
24
Kymera Therapeutics Inc
KYMR
8
13
2
0
0
23
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Biontech SE
BNTX
4
13
5
0
0
22
Revolution Medicines Inc
RVMD
8
12
1
0
0
21
Financial Forecasting
Based on analysts' estimates, ASND EPS is projected to reach 1.076 in FY2026Q3, following reported EPS of 3.678 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.05
0.24
1.60
1.08
1.56
Actual
-0.64
11.79
3.68
--
--
Surprise
-1134.29%
+4896.57%
+129.63%
--
--
FAQs
What is Ascendis Pharma A/S's expected revenue for the next quarter?
Ascendis Pharma A/S's expected revenue is 422.54M.
What is Ascendis Pharma A/S's price target?
Analysts forecast that Ascendis Pharma A/S's price target is USD 316.56, with the highest forecast at USD 382.27 and the lowest forecast at USD 270.00.
How have Ascendis Pharma A/SASND's recent earnings per share performed?
The market expectation was USD 3.68, while Ascendis Pharma A/SASND's earnings per share (EPS) for the previous quarter was USD 11.79. EPS for the next quarter is expected at USD 1.08.
What is the analyst rating for Ascendis Pharma A/S?
Based on the ratings of Ascendis Pharma A/S's stock from 20 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.